FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE
The invention relates to pharmaceutical compositions and dosage forms comprising full-length recombinant human parathyroid hormone (rhPTH(1-84)). The invention further relates to new and/or improved PTH compositions having improved in-use stability that are resistant to protein degradation in response to physical and chemical stresses.
1 . A pharmaceutical formulation comprising:
(a) a therapeutically effective amount of recombinant human parathyroid hormone (rhPTH(1-84));
(b) a surfactant;
(c) a tonicity agent;
(d) an antioxidant;
(e) a preservative;
(f) a physiologically acceptable buffer, and
(g) water,
wherein said pharmaceutical formulation is formulated as a liquid for injection, and wherein the formulation is physically stable and remains clear, colorless, and free of visible particles for at least 48 hours.
2 . The pharmaceutical formulation of claim 1 , wherein the formulation is physically stable for at least 72 hours.
3 . The pharmaceutical formulation of claim 1 , wherein the formulation is physically stable for at least 96 hours.
4 . The pharmaceutical formulation of claim 1 , wherein the formulation is physically stable for at least 7 days.
5 . The pharmaceutical formulation of claim 1 , wherein the formulation is physically stable for at least 14 days.
6 . The pharmaceutical formulation of claim 1 , wherein the formulation is physically stable for at least 21 days.
7 . The pharmaceutical formulation of claim 1 , wherein the surfactant is selected from Poloxamer-188 and polyethylene glycol, and combinations thereof.
8 . The pharmaceutical formulation of claim 1 , wherein the tonicity agent is selected from sodium chloride, sucrose, and glycerol, and combinations thereof.
9 . The pharmaceutical formulation of claim 1 , wherein the preservative is m-cresol, phenol, benzyl alcohol, sodium benzoate, propyl paraben, or combinations thereof.
10 . The pharmaceutical formulation of claim 1 , wherein the physiologically acceptable buffer is acetate buffer, phosphate buffer, L-Histidine buffer, or succinate buffer.
11 . The pharmaceutical formulation of claim 1 , further comprising an antioxidant.
12 . The pharmaceutical formulation of claim 11 , wherein the antioxidant is methionine, N-Acetyl-methionine, thiosulfate, N-Acetyl tryptophan, or combinations thereof.
13 . The pharmaceutical formulation of claim 1 having a pH of about 4 to about 6.
14 . The pharmaceutical formulation of claim 1 having a pH of about 5.5.
15 . The pharmaceutical formulation of claim 1 , wherein the formulation is in a unit-dose vial, a multi-dose vial, a cartridge, a pre-filled syringe, or an injection pen.
16 . A pharmaceutical formulation comprising:
(a) about 0.2 to about 2.0 mg/mL recombinant human parathyroid hormone (rhPTH(1-84));
(b) about 0.03% to about 3.0% w/v surfactant;
(c) about 0.2% to about 20% w/v tonicity agent;
(d) about 0.015% to about 1.50% w/v antioxidant;
(e) about 0.03% to about 3% preservative;
(f) about 5 mM to about 50 mM physiologically acceptable buffer, and
(g) water,
wherein said pharmaceutical formulation is formulated as a liquid for injection, and wherein the formulation is physically stable and remains clear, colorless, and free of visible particles for at least 48 hours.
17 . The pharmaceutical formulation of claim 16 , wherein the formulation is physically stable for at least 72 hours.
18 . The pharmaceutical formulation of claim 16 , wherein the formulation is physically stable for at least 96 hours.
19 . The pharmaceutical formulation of claim 16 , wherein the formulation is physically stable for at least 7 days.
20 . The pharmaceutical formulation of claim 16 , wherein the formulation is physically stable for at least 14 days.
21 . The pharmaceutical formulation of claim 16 , wherein the formulation is physically stable for at least 21 days.
22 . A pharmaceutical formulation comprising:
(a) a therapeutically effective amount of recombinant human parathyroid hormone (rhPTH(1-84));
(b) a bulking agent;
(c) a cryoprotectant, and
(d) a pharmaceutically acceptable buffer,
wherein said pharmaceutical formulation is formulated as a lyophilized powder to be reconstituted prior to injection, and wherein the formulation is physically stable and remains clear, colorless, and free of visible particles for at least 48 hours after reconstitution.
23 . The pharmaceutical formulation of claim 22 , wherein the formulation is physically stable for at least 72 hours.
24 . The pharmaceutical formulation of claim 22 , wherein the formulation is physically stable for at least 96 hours.
25 . The pharmaceutical formulation of claim 22 , wherein the formulation is physically stable for at least 7 days.
26 . The pharmaceutical formulation of claim 22 , wherein the formulation is physically stable for at least 14 days.
27 . The pharmaceutical formulation of claim 22 , wherein the formulation is physically stable for at least 21 days.
28 . The pharmaceutical formulation of claim 22 , wherein the bulking agent is mannitol.
29 . The pharmaceutical formulation of claim 22 , wherein the cryoprotectant is sucrose.
30 . The pharmaceutical formulation of claim 22 , wherein the pharmaceutically acceptable buffer is acetate buffer, phosphate buffer, L-Histidine buffer, or succinate buffer.
31 . The pharmaceutical formulation of claim 22 , wherein the pharmaceutically acceptable buffer is L-Histidine buffer.
32 . The pharmaceutical formulation of claim 31 having a pH of about 5.5.
33 . The pharmaceutical formulation of claim 22 , wherein the pharmaceutically acceptable buffer is succinate buffer.
34 . The pharmaceutical formulation of claim 33 having a pH of between about 4 and about 4.5.
35 . The pharmaceutical formulation of claim 22 , further comprising an antioxidant and/or a surfactant.
36 . The pharmaceutical formulation of claim 35 , wherein the antioxidant is methionine and the surfactant is Poloxamer-188.
37 . A pharmaceutical formulation comprising:
(a) about 0.02 to about 2.0 mg/mL recombinant human parathyroid hormone (rhPTH(1-84));
(b) about 0.3% to about 30% w/v bulking agent;
(c) about 0.2% to about 20% w/v cryoprotectant, and
(d) about 5 mM to about 50 mM pharmaceutically acceptable buffer,
wherein said pharmaceutical formulation is formulated as a lyophilized powder to be reconstituted prior to injection, and wherein the formulation is physically stable and remains clear, colorless, and free of visible particles for at least 48 hours after reconstitution.
38 . The pharmaceutical formulation of claim 37 , wherein the formulation is physically stable for at least 72 hours.
39 . The pharmaceutical formulation of claim 37 , wherein the formulation is physically stable for at least 96 hours.
40 . The pharmaceutical formulation of claim 37 , wherein the formulation is physically stable for at least 7 days.
41 . The pharmaceutical formulation of claim 37 , wherein the formulation is physically stable for at least 14 days.
42 . The pharmaceutical formulation of claim 37 , wherein the formulation is physically stable for at least 21 days.
43 . A kit for formulating an injectable solution of rhPTH(1-84) comprising a first container comprising the pharmaceutical formulation of claim 22 , a second container comprising sterile water for reconstituting said pharmaceutical formulation, and a sheet instructing preparation of a reconstituted formulation therefrom.
44 . The kit of claim 43 , further comprising a device for injection of the reconstituted rhPTH(1-84) solution.
45 . A method of administering a therapeutically effective amount of rhPTH(1-84) to a subject in need thereof, comprising subcutaneously, intravenously, or intramuscularly injecting the pharmaceutical formulation of claim 1 into the subject.
46 . The method of claim 45 , wherein the injecting is performed with a syringe, an auto-injector, an injection pen, or a combination thereof.
47 . A method of administering a therapeutically effective amount of rhPTH(1-84) to a subject in need thereof, comprising
(i) reconstituting the pharmaceutical formulation of claim 22 with sterile water, and
(ii) subcutaneously, intravenously, or intramuscularly injecting the reconstituted formulation into the subject.
48 . The method of claim 47 , wherein the injecting is performed with a syringe, an auto-injector, an injection pen, or a combination thereof.